We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02132624
Recruitment Status : Completed
First Posted : May 7, 2014
Last Update Posted : October 30, 2017
Uppsala University Hospital
Karolinska University Hospital
AFA Insurance
Swedish Cancer Society
Information provided by (Responsible Party):
Uppsala University